newsfilter
← Latest News
GlobeNewswire·

Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes